Filters
New drug applications approved by US FDA as of 16-31 May 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
New drug applications approved by US FDA as of 1-15 May 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
High-dose inactivated influenza vaccine (HD-IIV) confers improved protection against hospitalization outcomes for older adults when compared with standard-dose inactivated influenza vaccine (SD-IIV), according to the results of a meta-analysis.
The novel antisense oligonucleotide bepirovirsen has induced functional cure in one-fifth of patients with chronic hepatitis B virus (HBV) infection in the phase 3 B-Well 1 and B-Well 2 trials.
Individuals with chronic hepatitis D (CHD) may benefit from lonafarnib boosted with ritonavir (LNF/RTV) alone or in combination with peg-interferon-alfa (PEG), findings from the phase III D-LIVR trial have shown.
Hepatitis B virus (HBV) low-level viraemia (LLV) may increase the risk of liver-related events, as suggested in a study.
Recent COVID-19 vaccination has been linked to a reduced risk of SARS-CoV-2 transmission in a prospective, case-ascertained household transmission study.
HIV-positive patients with variceal upper gastrointestinal bleeding (VUGIB) may experience worse clinical outcomes and poor survival, according to a study.
A study shows that daily nasal interferon-alpha (IFN-α) spray reduces the incidence of COVID-19 among adult patients with cancer.
Treatment with paediatric dolutegravir-containing antiretroviral therapy (ART) results in robust virologic response among children living with HIV (CLHIV), reports a Cameroon study.
